FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer - AstraZeneca (NASDAQ:AZN)

AstraZeneca and Daiichi Sankyo Treatment Wins First of Its Kind FDA Blessing to Treat Lung Cancer

AstraZeneca paid Japan’s Daiichi Sankyo a whopping $1 billion upfront back in 2020, and tacked on a potential $5 billion in milestone payments, for the chance to co-develop the antibody-drug conjugate DS-1062 outside of Japan. On Tuesday, the treatment, marketed as Datroway, was given the greenlight by the US Food and Drug Administration to treat a specific lung cancer, making it the first therapy of its kind to be approved for treating the dise…

AZ, Daiichi get Datroway nod in lung cancer on second try

AZ and Daiichi Sankyo have claimed FDA approval for Datroway in lung cancer after switching indications for the TROP2-directed drug.

FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer - AstraZeneca (NASDAQ:AZN)

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.

US approves AstraZeneca, Daiichi's treatment for lung cancer

(Reuters) -AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this indication and expanding access for patients.

FDA Grants Accelerated Approval for DATROWAY in Advanced EGFR-Mutated Lung Cancer

WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has granted accelerated approval to DATROWAY® (datopotamab deruxtecan-dlnk) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have previously received EGFR-directed therapy and platinum-based chemotherapy. This milestone approval follows Priority Review and Breakthrough Therapy Designation and is based on promisi…

FDA Approves Datroway (datopotamab deruxtecan-dlnk) for EGFR-positive NSCLC  - GO2 for Lung Cancer

Open the article to view the coverage from go2.org